Associated tags: FDA, Water purification, Dialysis, Patient, Health, Medical Devices, Medicine, Health Technology, Pharmaceutical industry, Medical device
Locations: US, SILICON VALLEY, NEW YORK, NY, LONDON, LOS ANGELES, CHICAGO, PARIS, TEL AVIV, PENNSYLVANIA, CA, MICHIGAN, MASSACHUSETTS, SEATTLE, WA, PA, PHILADELPHIA, ALASKA, UNITED STATES, NORTH AMERICA, CALIFORNIA, STRYKER
Person,
FDA,
OM,
Letter,
Dialysis,
Hagens Berman,
SAN,
Life insurance,
Medical device,
Pharmaceutical industry,
Outset Contemporary Art Fund SAN FRANCISCO, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Outset Medical, Inc. (NASDAQ: OM) investors who suffered substantial losses to submit your losses now .
Key Points:
- SAN FRANCISCO, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Outset Medical, Inc. (NASDAQ: OM) investors who suffered substantial losses to submit your losses now .
- In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
- More recently, on Oct. 12, 2023, Outset Medical reported disappointing preliminary Q3 2023 revenues and slashed its FY 2023 revenue guidance.
- “We’re focused on investors’ losses and investigating whether Outset may have misled investors about Tablo’s near-term prospects,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
Retrieved on:
Wednesday, November 1, 2023
Health,
Medical Devices,
Health Technology,
Managed Care,
General Health,
Clinical Trials,
Biotechnology,
Patient,
Medicare,
Experiment (probability theory),
Learnability,
Medicine,
HHD,
MD,
Nephrology,
Research,
Society,
Dialysis,
ASN,
Abstract,
Pythagorean Method of Memorization,
Kidney,
PRO,
Insomnia,
Health insurance,
Pharmaceutical industry,
Nursing,
Medical device,
Outset Contemporary Art Fund,
Tablo The five abstracts will be showcased at the American Society of Nephrology’s (ASN) Kidney Week 2023 in Philadelphia, PA, which runs November 2-5.
Key Points:
- The five abstracts will be showcased at the American Society of Nephrology’s (ASN) Kidney Week 2023 in Philadelphia, PA, which runs November 2-5.
- The annual event gathers more than 10,000 kidney care professionals from across the globe, offering a forum to delve into the latest advancements in nephrology and to collaborate on kidney care innovation.
- "The research abstracts we're presenting at ASN Kidney Week are more than data points; they are a testament to Tablo's adaptability, versatility and its profound impact on equitable healthcare,” said Michael Aragon, MD, Chief Medical Officer of Outset Medical.
- Attendees are invited to visit the Outset booth (#1117) during the ASN meeting for more information.
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 7, 2023.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the third quarter of 2023 after the close of trading on Tuesday, November 7, 2023.
- On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer, will host a conference call to discuss financial and operating results.
- The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Tuesday, November 7, 2023.
- A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/ .
Retrieved on:
Thursday, October 19, 2023
FDA,
Novo Nordisk,
News,
Diabetes,
CRRT,
Hemofiltration,
Chronic kidney disease,
Pomerantz,
LLP,
Marketing,
Health,
Letter,
Pharmaceutical industry NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).
Key Points:
- NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. (“Outset” or the “Company”) (NASDAQ: OM).
- Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
- The investigation concerns whether Outset and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
Retrieved on:
Thursday, October 19, 2023
As a result, Outset suspended 2022 and long-term financial guidance.
Key Points:
- As a result, Outset suspended 2022 and long-term financial guidance.
- In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
- More recently, on Oct. 12, 2023, Outset Medical reported disappointing preliminary Q3 2023 revenues and slashed its FY 2023 revenue guidance.
- “We’re focused on investors’ losses and investigating whether Outset may have misled investors about Tablo’s near-term prospects,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
Retrieved on:
Tuesday, October 17, 2023
LOS ANGELES, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors. Outset Medical that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Key Points:
- LOS ANGELES, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Outset Medical, Inc. (“Outset Medical” or the “Company”) (NASDAQ: OM ) investors that the firm has initiated an investigation into possible securities violations and may file a class action on behalf of investors.
- Outset Medical that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
- The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
- The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.
Retrieved on:
Saturday, October 14, 2023
In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
Key Points:
- In late July 2022, Outset disclosed the FDA cleared the 510(k) application of Tablo for patient use in the home.
- More recently, on Oct. 12, 2023, Outset Medical reported disappointing preliminary Q3 2023 revenues and slashed its FY 2023 revenue guidance.
- “We’re focused on investors’ losses and investigating whether Outset may have misled investors about Tablo’s near-term prospects,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
- If you invested in Outset Medical and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman .
Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Outset Medical Inc. ("Outset" or the "Company") (NASDAQ: OM), a medical technology company based in San Jose, California.
Key Points:
Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Outset Medical Inc. ("Outset" or the "Company") (NASDAQ: OM), a medical technology company based in San Jose, California.
Retrieved on:
Thursday, October 12, 2023
FDA,
Diabetes,
Medical Devices,
Health,
Health Technology,
Investment,
Bank statement,
Webcast,
Growth,
Appendix,
GAAP,
Letter,
Medicine,
Cryptocurrency,
Bank Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), today announced preliminary financial results for the third quarter ended Sept. 30, 2023, and provided updated financial guidance for 2023.
Key Points:
- Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), today announced preliminary financial results for the third quarter ended Sept. 30, 2023, and provided updated financial guidance for 2023.
- Preliminary revenue for the third quarter was $30.4 million, a 9% increase over revenue of $27.8 million in the third quarter of 2022.
- Preliminary gross margin for the third quarter was 23.6%, or 25.6% on a non-GAAP basis, compared to 16.4% on a non-GAAP basis in the third quarter of 2022.
- ET to discuss its preliminary third quarter 2023 results.
Nursing,
Medical Devices,
Hospitals,
Health Technology,
Health Insurance,
Biotechnology,
Physical Therapy,
Managed Care,
Health,
Medicine,
Business development,
Senior,
VGM,
Business,
HME,
Kidney,
Dialysis,
Hospital,
Patient,
Nephrology,
Trace,
Home medical equipment,
GPO,
FDA,
Corporate title,
Medical device Trace Medical , the national leader in advanced respiratory rentals and biomedical services, has announced a long-term distribution agreement with Outset Medical to rent the Tablo® Hemodialysis System to Home Medical Equipment (HME) providers.
Key Points:
- Trace Medical , the national leader in advanced respiratory rentals and biomedical services, has announced a long-term distribution agreement with Outset Medical to rent the Tablo® Hemodialysis System to Home Medical Equipment (HME) providers.
- As part of this agreement, Trace Medical will leverage its national distribution network to offer HME providers exclusive access to rent Tablo and meet the growing demand of dialysis patients seeking treatment at home.
- Greg Apostolou, Chief Executive Officer of Trace Medical, stated, “We are excited to work with Outset to fill an obvious need in dialysis treatment.
- For providers, hospitals, or dialysis centers that would like to learn more about a rental solution for dialysis from Trace Medical, please email [email protected] .
